

## SUPPLEMENTARY TABLE

**Supplementary Table 3. Results of quality assessment of included studies.**

Study	Selection			Comparability		Outcome		Total score	
	Representativeness of exposed cohort★	Selection of non-exposed cohort★	Exposure ascertainment★	No history of disease★	Comparable on confounders★★	Outcome assessment★	Adequate follow-up (≥10y)★		Loss to follow-up rate (≤20%)★
Ha et al. (2020) [33]		★	★	★	★		★	★	6
Hu et al. (2020) [32]		★	★	★	★		★	★	6
Su et al. (2020) [19]	★	★	★	★	★	★	★	★	8
Shin et al. (2020) [31]	★	★	★	★	★	★	★	★	8
Papatheodoridis et al. (2020) [18]	★	★	★	★	★	★		★	7
Oh et al. (2020) [17]		★	★	★	★	★	★	★	7
Ha et al. (2002) [16]		★	★	★	★		★	★	6
Lee et al. (2019) [10]		★	★	★	★	★	★	★	7
Kim et al. (2019) [11]		★	★	★	★		★	★	6
Hsu et al. (2019) [12]	★	★	★	★	★		★	★	7
Choi et al. (nationwide cohort) (2019) [15]	★	★	★	★	★	★	★	★	8
Choi et al. (validation hospital cohort) (2019) [15]		★	★	★	★	★	★	★	7
Yip et al. (2019) [14]	★	★	★	★	★	★	★	★	8
Kim et al. (2018) [13]		★	★	★	★		★	★	6

Note that the reference numbers refer to the reference list in the main article.